Robert W. Azelby

Robert Azelby is an experienced executive in the biotechnology and pharmaceutical sectors, currently serving as a member of the Board of Directors for Cardinal Health, Autolous Therapeutics, and ADC Therapeutics. Azelby's previous roles include serving as the President and CEO of Eliem Therapeutics and Alder Biopharmaceuticals, both of which were later acquired by larger companies. Azelby also held significant positions at Juno Therapeutics, where responsibilities included developing the commercial strategy and leading the organization through its acquisition by Celgene. Educational qualifications include an MBA from Harvard Business School and a BA in Economics and Religious Studies from the University of Virginia.